Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC-20057, USA.
Cancer Biomark. 2010;9(1-6):65-99. doi: 10.3233/CBM-2011-0173.
In an effort to improve our understanding and treatment of cancer, a new model of tumorigenesis is being developed - the cancer stem cell model. Building upon traditional concepts of cancer and stem cells, this model is intended to shed new light on the continuing struggle with treatment challenges such as tumor drug-resistance and recurrence. This review describes the cancer stem cell model with an emphasis on delineating markers that represent a "stemness" phenotype within certain tumor cells. The objective of this delineation is to develop targeted therapies for the selective elimination of cancer stem cells with minimal toxicity to normal stem cells and tissues. However, this specific targeting of cancer stem cells has proved to be a significant challenge due to the similarity of markers expressed by both normal and cancer stem cells. Still, research in the area of cancer biomarkers is steadily progressing.
为了提高我们对癌症的理解和治疗水平，一种新的肿瘤发生模型——癌症干细胞模型正在被开发。该模型以传统的癌症和干细胞概念为基础，旨在为持续存在的治疗挑战（如肿瘤耐药性和复发）提供新的思路。本综述描述了癌症干细胞模型，重点阐述了在某些肿瘤细胞中代表“干性”表型的标志物。这种描绘的目的是开发针对癌症干细胞的靶向疗法，以最小的毒性选择性地消除癌症干细胞，而对正常干细胞和组织的毒性最小。然而，由于正常和癌症干细胞表达的标志物相似，这种对癌症干细胞的特定靶向已被证明是一个重大挑战。尽管如此，癌症生物标志物领域的研究仍在稳步推进。
